G
Giorgio Bolis
Researcher at Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Publications - 66
Citations - 4497
Giorgio Bolis is an academic researcher from Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico. The author has contributed to research in topics: Ovarian cancer & Chemotherapy. The author has an hindex of 25, co-authored 66 publications receiving 4279 citations.
Papers
More filters
Journal ArticleDOI
A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project.
Giancarlo Agnelli,Giorgio Bolis,Lorenzo Capussotti,Roberto Mario Scarpa,Francesco Tonelli,Erminio Bonizzoni,Marco Moia,Fabio Parazzini,Romina Rossi,Francesco Sonaglia,Bettina Valarani,Carlo Bianchini,Gualberto Gussoni +12 more
TL;DR: In patients undergoing cancer surgery, VTE is the most common cause of death at 30 days after surgery, and a remarkable proportion of events occurring late after surgery is found.
Journal ArticleDOI
Impact of Adjuvant Chemotherapy and Surgical Staging in Early-Stage Ovarian Carcinoma: European Organisation for Research and Treatment of Cancer–Adjuvant ChemoTherapy in Ovarian Neoplasm Trial
J. Baptist Trimbos,Ignace Vergote,Giorgio Bolis,Jan B. Vermorken,Constantino Mangioni,Caterina Madronal,Massimo Franchi,Saverio Tateo,Gerardo Zanetta,Giovanna Scarfone,Livia Giurgea,Petra Timmers,Corneel Coens,Sergio Pecorelli +13 more
TL;DR: The benefit of adjuvant chemotherapy appeared to be limited to patients with non-optimal staging, i.e., patients with more risk of unappreciated residual disease, and adjuvant chemotherapy was associated with statistically significantly improved recurrence-free survival in patients with early-stage ovarian cancer.
Journal ArticleDOI
International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma.
J. Baptist Trimbos,Mahesh K. B. Parmar,Ignace Vergote,David Guthrie,Giorgio Bolis,Nicoletta Colombo,Jan B. Vermorken,Valter Torri,Constantino Mangioni,Sergio Pecorelli,Andrea Lissoni,Ann Marie Swart +11 more
TL;DR: Platinum-based adjuvant chemotherapy improved overall survival and recurrence-free survival at 5 years in this combined group of patients with early-stage ovarian cancer defined by the inclusion criteria of the ICON1 and ACTION trials.
Journal ArticleDOI
Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study.
G. J. Creemers,Giorgio Bolis,M Gore,Giovanna Scarfone,A J Lacave,J P Guastalla,R. Despax,G Favalli,R Kreinberg,S Van Belle,I. Hudson,Jaap Verweij,W W ten Bokkel Huinink +12 more
TL;DR: Topotecan in a daily-times-five schedule is an effective regimen as second-line treatment in ovarian cancer in patients who had failed to respond to one prior cisplatin-based chemotherapeutic regimen.
Journal ArticleDOI
Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel.
Michael A. Bookman,Henric Malmström,Giorgio Bolis,Alan Gordon,Andrea Lissoni,Jacqueline B. Krebs,Scott Z. Fields +6 more
TL;DR: As a single agent, topotecan has modest activity in women with advanced epithelial ovarian carcinoma who have progressed or not responded after one or two prior regimens with platinum and paclitaxel.